Good morning :)
Innova Captab Ltd

Innova Captab Ltd

INNOVACAP Share Price

NSE
1,179.802.58% (+29.70)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹6,751 cr, stock is ranked 753

Stock is 2.63x as volatile as Nifty

INNOVACAP Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹6,751 cr, stock is ranked 753

Stock is 2.63x as volatile as Nifty

INNOVACAP Performance & Key Metrics

INNOVACAP Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
43.836.190.17%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
47.205.920.48%

INNOVACAP Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

INNOVACAP Company Profile

Innova Captab Ltd is an integrated pharmaceutical company involved in manufacturing and trading drugs, offering services across R&D, manufacturing, and distribution of generic formulations and branded generics.

Investor Presentation

View older View older 

Aug 11, 2026

PDF
View Older Presentations

INNOVACAP Similar Stocks (Peers)

Compare with peers Compare with peers 

INNOVACAP Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
Compare with Peers

INNOVACAP Sentiment Analysis

INNOVACAP Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

INNOVACAP Stock Summary · May 2026

Strong top‑line momentum underpinned the call, with consolidated FY'26 revenue of INR 1,630 crore and EBITDA rising to INR 250.3 crore, reflecting broad-based volume‑led growth across CDMO and branded generics. Management struck an upbeat, execution‑focused tone, highlighting customer wins, geographic expansion in branded markets, the strategic benefit of recent regulatory credentials, and R&D investments — including a measured, wave‑2 approach to semaglutide — to move into higher value‑added work. They noted meaningful contrast between robust group growth and near‑term operating unevenness as a recently commissioned Jammu site remains underutilized; management reported Jammu is nearing EBITDA breakeven and should start covering fixed costs imminently, which they expect to unlock operating‑leverage benefits as utilization improves. Management also flagged ongoing capital plans to expand Baddi capacity and to commercialize regulated‑market opportunities from the Sharon acquisition, and explained that accounting choices (capitalizing project costs and prior depreciation/finance impact) will support margin expansion. For FY'27 they reiterated a consolidated target of 20%+ revenue growth driven by sustained volume gains.

INNOVACAP Stock Growth Drivers
INNOVACAP Stock Growth Drivers
10
  • Record FY'26 Financial Performance

    The company delivered milestone FY'26 results with consolidated revenue of INR 1,630 crore, up 31%

  • Broad‑Based Segment Growth: CDMO and Branded Generics

    Growth in FY'26 was broad‑based across the CDMO and Branded Generics businesses: CDMO revenue reached

INNOVACAP Stock Challenges
INNOVACAP Stock Challenges
4
  • Rising input-cost and geopolitical API-price risk

    Management acknowledged that input prices are increasing due to supply-side disruptions and investors flagged a

  • Realized gross-margin deterioration driven by adverse product mix

    The company reported a year‑on‑year gross margin decline and explicitly attributed the deterioration primarily to

INNOVACAP Forecast

INNOVACAP Forecasts

Price

Revenue

Earnings

INNOVACAP

INNOVACAP

Income

Balance Sheet

Cash Flow

INNOVACAP Income Statement

INNOVACAP Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue268.32296.39320.42320.79318.12356.03384.57451.95449.37472.86
Operating & Other expensessubtract224.56252.09268.47269.90267.06299.44328.52380.90382.71397.73
Depreciation/Amortizationsubtract3.414.854.995.139.8011.0511.3211.4211.3911.71
Interest & Other Itemssubtract0.810.140.150.171.952.865.503.954.594.43
Taxes & Other Itemssubtract10.829.8411.8111.399.7411.679.5713.5312.5914.86
EPS5.025.156.125.975.175.425.187.376.657.71

INNOVACAP Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Aug 11PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 7PDF
Jan 23PDF
Nov 7PDF
Aug 7PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 19PDF
Feb 5PDF
Nov 7PDF
FY 2024FY 2024

Annual report

PDF
 

INNOVACAP Stock Peers

INNOVACAP Past Performance & Peer Comparison

INNOVACAP Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Innova Captab Ltd47.916.190.17%
Sun Pharmaceutical Industries Ltd38.405.260.87%
Torrent Pharmaceuticals Ltd85.1010.470.70%
Zydus Lifesciences Ltd22.963.910.09%

INNOVACAP Stock Price Comparison

Compare INNOVACAP with any stock or ETF
Compare INNOVACAP with any stock or ETF
INNOVACAP
Loading...

INNOVACAP Holdings

INNOVACAP Shareholdings

INNOVACAP Promoter Holdings Trend

INNOVACAP Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

INNOVACAP Institutional Holdings Trend

INNOVACAP Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

INNOVACAP Shareholding Pattern

INNOVACAP Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.90%9.18%10.74%0.34%28.84%

Sep 2025

Dec 2025

Mar 2026

Jun 2026

INNOVACAP Shareholding History

INNOVACAP Shareholding History

MarJunSepDec '25MarJun0.34%0.23%0.08%0.11%0.23%0.34%

Mutual Funds Invested in INNOVACAP

Mutual Funds Invested in INNOVACAP

No mutual funds holding trends are available

Top 5 Mutual Funds holding Innova Captab Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
2.6924%0.60%-0.03%31/84 (0)
2.6028%1.20%0.06%70/97 (-4)
1.0060%0.43%-0.03%30/76 (0)

Compare 3-month MF holding change on Screener

INNOVACAP Insider Trades & Bulk Stock Deals

INNOVACAP Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing INNOVACAP stock

smallcases containing INNOVACAP stock

Looks like this stock is not in any smallcase yet.

INNOVACAP Events

INNOVACAP Events

INNOVACAP Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

INNOVACAP Dividend Trend

No dividend trend available

INNOVACAP Upcoming Dividends

INNOVACAP Upcoming Dividends

No upcoming dividends are available

INNOVACAP Past Dividends

INNOVACAP Past Dividends

Cash Dividend

Ex DateEx DateJan 30, 2026

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jan 30, 2026

INNOVACAP Stock News & Opinions

INNOVACAP Stock News & Opinions

Corporate
Corporate
Innova Captab to acquire land with an estimated Rs 50 crore investment

Innova Captab Limited announced that its board of directors has given in-principle approval for the acquisition of land with an estimated investment of Rs 50,00,00,000, according to a filing with the BSE Limited and National Stock Exchange of India Limited on September 3, 2026.

2 weeks agoCapital Market - Live
Corporate
Corporate
Innova Captab to revise financial statements following inadvertent errors identified

Innova Captab Limited will hold a board meeting on Friday, August 21, 2026, to revise its standalone and consolidated financial statements for the quarter and financial year ended March 31, 2026, following the identification of inadvertent errors in previously adopted financial statements, including those of entities within its group. The trading window for designated persons and their immediate relatives, which was closed from July 1, 2026, and extended on August 13, 2026, will reopen 48 hours after the revised financial statements are declared.

1 month agoCapital Market - Live
Corporate
Corporate
Innova Captab closes securities trading window ahead of financial results release

Innova Captab Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company's securities will remain closed for all designated persons and their immediate relatives until 48 hours after the declaration of the revised audited financial statements for the quarter and financial year ended March 31, 2026.

1 month agoCapital Market - Live
Earnings
Earnings
Innova Captab Ltd consolidated sales up 5.15% on year in Q2FY2026, net profit expanded by 15.89%

Innova Captab Ltd share price headed higher 5.49% to Rs 1021.45 after the company's net profit rose by 15.89% to Rs 44.13 crore, while revenue from operations improved marginally 5.15% to Rs 470.85 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, easing 4.54%. It has marginally improved by 1.41% over last one week and moving up by 14.23% in last one month while the market capitalization of Innova Captab Ltd has inched up 8.47% and 16.71% in the same period respectively. Profit before tax (PBT) of Innova Captab Ltd stood at Rs 58.99 crore in Q2 FY26, jumping 38.21% year-on-year, and rallying 16.40% quarter-on-quarter. EBITDA came in at Rs 71 crore, surging by 49.33% YoY and rising by 11.91% sequentially. Total expenses posted a minor rise of 3.89% to Rs 409.45 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 307.98 crore, rising 17.89% YoY, while employee benefits expense was at Rs 44.79 crore, inching up 5.09% YoY. For the TTM ended FY26, revenue from operations soared by 31.06% to Rs 1630.02 crore, while net profit saw a mild growth of 9.87% to Rs 140.92 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 19351% to Rs 235.5 crore, and PBT rose 10.08% to Rs 188.26 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 116.52 crore in FY26, as against Rs 63.84 crore in FY25. Innova Captab Ltd climbed 7.60% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.

1 month agoCapital Market - Live
Corporate
Corporate
Innova Captab to review financial results at board meeting on August 11, 2026

Innova Captab Limited will hold a board meeting on Tuesday, August 11, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and the revised audited standalone financial results for the quarter and financial year ended March 31, 2026, along with related statements, necessitated by an immaterial inadvertent error. The trading window for securities of Innova Captab Limited will reopen 48 hours after the financial results are declared, having been closed since July 1, 2026, for designated persons and their immediate relatives.

1 month agoCapital Market - Live
Corporate
Corporate
Innova Captab AGM scheduled

Innova Captab announced that the Annual General Meeting(AGM) of the company will be held on 29 June 2026.

3 months agoCapital Market - Live
Earnings
Earnings
Innova Captab consolidated net profit rises 28.78% in the March 2026 quarter

Net profit of Innova Captab rose 28.78% to Rs 38.08 crore in the quarter ended March 2026 as against Rs 29.57 crore during the previous quarter ended March 2025. Sales rose 42.28% to Rs 447.80 crore in the quarter ended March 2026 as against Rs 314.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 9.87% to Rs 140.92 crore in the year ended March 2026 as against Rs 128.26 crore during the previous year ended March 2025. Sales rose 31.06% to Rs 1630.02 crore in the year ended March 2026 as against Rs 1243.68 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales447.80314.74 42 1630.021243.68 31 OPM %14.5415.15 -14.9014.97 - PBDT62.0649.11 26 233.44195.80 19 PBT50.6839.31 29 188.26171.02 10 NP38.0829.57 29 140.92128.26 10 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Corporate
Innova Captab to announce Quarterly Result

Innova Captab will hold a meeting of the Board of Directors of the Company on 7 May 2026.

4 months agoCapital Market - Live
Earnings
Earnings
Innova Captab consolidated net profit rises 23.25% in the December 2025 quarter

Net profit of Innova Captab rose 23.25% to Rs 42.15 crore in the quarter ended December 2025 as against Rs 34.20 crore during the previous quarter ended December 2024. Sales rose 42.29% to Rs 450.29 crore in the quarter ended December 2025 as against Rs 316.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales450.29316.46 42 OPM %15.4114.71 - PBDT67.1050.72 32 PBT55.6845.59 22 NP42.1534.20 23 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Corporate
Innova Captab incorporates subsidiary named Metal Mart

Innova Captab has incorporated a subsidiary company named Metal Mart on 22 January 2026. The company will hold 70% stake in Metal Mart. Powered by Capital Market - Live

7 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. The share price of INNOVACAP as on 18th September 2026 is ₹1179.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Innova Captab Ltd (INNOVACAP) share are
    • Past 1 week: 2.24%
    • Past 1 month: 13.31%
    • Past 3 months: 26.46%
    • Past 6 months: 67.35%
    • Past 1 year: 37.57%
    • Past 3 years: N/A%
    • Past 5 years: 117.92%

  3. The current dividend yield of Innova Captab Ltd (INNOVACAP) is 0.17.

  4. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Innova Captab Ltd (INNOVACAP) is ₹6751.40 Cr as of 18th September 2026.

  5. The 52-week high of Innova Captab Ltd (INNOVACAP) is ₹1236.10 and the 52-week low is ₹622.

  6. The P/E (price-to-earnings) ratio of Innova Captab Ltd (INNOVACAP) is 47.91. The P/B (price-to-book) ratio is 6.19.

  7. Innova Captab Ltd (INNOVACAP) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. You can directly buy Innova Captab Ltd (INNOVACAP) shares on Tickertape. Simply sign up, connect your demat account and place your order.